ARTL Stock Analysis: Buy, Sell, or Hold?
ARTL - Artelo Biosciences, Inc. Common Stock
$0.69
0.00 (-0.43%)
âŧ
5d:
-4.44%
30d:
-32.45%
90d:
-42.1%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When ARTL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ARTL is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ARTL is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ARTL is currently trading at $0.69, which is considered slightly low relative to its 30-day fair value range of $0.73 to $1.07.
Technical Outlook: Technically, ARTL is in a strong downtrend. Immediate support is located at $0.66, while resistance sits at $0.91.
Market Sentiment: ARTL scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.00 (+2512.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ARTL is in a strong downtrend. Immediate support is located at $0.66, while resistance sits at $0.91.
Market Sentiment: ARTL scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.00 (+2512.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.73 -
$1.07
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 2512.5% below Wall St target ($18.00)
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.73 -
$1.07
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.66
Resistance Level
$0.91
Current Trend
Strong Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.13
Wall Street Target
$18.00
(+2512.5%)
Share & Embed Analysis
Last updated: August 25, 2026 3:51 AM ET
Data refreshes hourly during market hours. Next update: 4:51 AM
Data refreshes hourly during market hours. Next update: 4:51 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARTL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 38 SELL |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$560 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 50 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
